posting velocity //
Opens vs closes per day
Based on 12 events over 25 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
Showing: Israel. Click another pill to switch.
Open now
6
Total active openings across all sites
Δ 28-day
+6
Opens minus closes in the last 28 days
Δ 90-day
+6
Opens minus closes in the last 90 days
posting velocity //
Based on 12 events over 25 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
role mix //
The green layer is the current share of active openings by role. The grey dashed layer is the 90-day baseline — gaps between them show where the company is shifting its hiring mix.
seniority pyramid //
Distribution of active openings by seniority. The 'unknown' row groups jobs from sources that don't expose seniority.
geography //
Active openings by region. Click a row to see jobs in that area.
time on market //
Median
Soon
25th pct
6.4 days
75th pct
Soon
Based on 3 closed jobs and 6 still open (right-censored). Curve is Kaplan-Meier; band is the 95% CI.Still collecting — median tracking age is ~8.7 days (need 14+). 67% of closures were within 3 days, which often reflects feed churn rather than hires.
Window: 180 days back. Don't read the mean — the long tail biases it. Median and percentiles are the honest summary.
Republish rate
—
Fewer than 10 closures in the window — not enough to compute.
company intel · ai-generated
Updated 7d ago
Teva Pharmaceutical Industries is the world's largest generic drug manufacturer, with its international headquarters located in Petah Tikva, Israel. The company is listed on the New York Stock Exchange under the ticker TEVA and is also traded on the Tel Aviv Stock Exchange. Teva is one of Israel's largest publicly traded companies by market capitalization.
Teva develops, manufactures, and markets generic and branded pharmaceuticals. Generic drugs form the core of its business: Teva supplies generic versions of a broad range of prescription medicines to markets in North America, Europe, and Asia. On the branded side, the most prominent product has been Copaxone (glatiramer acetate) for the treatment of multiple sclerosis, which for many years was the primary revenue driver in the branded segment. As Copaxone's patents expired, its dominance in the company's revenue mix declined.
Teva's key products include Copaxone (glatiramer acetate) for multiple sclerosis and AJOVY (fremanezumab) for the prevention and treatment of migraines, which received FDA approval in 2018. The company also maintains a broad portfolio of generic drugs sold under various trade names across different markets.
Teva competes with major generic pharmaceutical companies including Mylan (now Viatris), Sandoz (a Novartis division), and Sun Pharma. In recent years the company has faced significant challenges: a heavy debt load stemming in part from the 2016 acquisition of Actavis Generics from Allergan for approximately $40.5 billion — the largest acquisition in the company's history — as well as settlement agreements related to opioid-related litigation in the United States. The company has also faced regulatory investigations and lawsuits related to generic drug pricing in the U.S.
The international headquarters are in Petah Tikva. Teva maintains manufacturing, R&D, and administrative operations in Israel and is one of the largest employers in the domestic pharmaceutical sector. It operates production facilities in Israel alongside an extensive global manufacturing network.
key people & leadership
1 key people, sourced from public records — with a per-row confidence score.
Richard Francis
President and CEO
hiring signal · from our data
From our job data · always current
6 open roles in Israel
Live openings we track — Israel first, plus worldwide when we have them.
news feed
No recent news about this company.